Johan Hartman

Professor Johan Hartman is a leading academic and clinician at Karolinska Institutet, serving as a Professor and Senior Consultant in the Department of Oncology-Pathology. His primary role combines research leadership in precision pathology with clinical expertise in breast pathology at Karolinska University Hospital. Hartman leads a research group focused on personalized breast cancer therapy through advanced technologies like AI-driven histopathology analysis, molecular genomics, and patient-derived tumor models.

Education & Qualifications:

• Doctoral Degree (2008), Karolinska Institutet
• Medical Degree (2008), Karolinska Institutet
• Docent (2015), Karolinska Institutet

Research Focus:

Hartman’s lab pioneers innovations in precision medicine, particularly in predicting treatment responses using digital pathology, AI, and genomic profiling. Key areas include tumor heterogeneity, AI tools for diagnostic accuracy, and translational research linking molecular profiles to clinical outcomes. His group has developed clinical-grade AI systems for breast cancer risk stratification and tumor characterization.

Publications & Impact:

With over 100 peer-reviewed articles in high-impact journals (e.g., Science, Nature Communications), Hartman’s work emphasizes breast cancer therapy prediction, immune profiling, and molecular diagnostics. Recent studies include AI-driven TIL analysis, spatial transcriptomics, and genomic heterogeneity in tumors.

Awards & Recognition:

• 2023 Karolinska Institutet Innovation Award
• 2022 Athena Prize (Vetenskapsrådet)
• 2016 Clinical Investigator Award (Swedish Cancer Society)

Grants & Collaborations:

• Leading projects funded by Radiumhemmets Forskningsfonder, Vinnova, and industry partnerships
• Co-founder of Stratipath, a KI spin-off advancing precision pathology tools

Labs & Teams:

Hartman’s group includes postdocs, PhD students, and clinical researchers. Key members focus on AI in pathology, tumor modeling, and translational oncology. The team collaborates internationally on initiatives like the International Immuno-Oncology Biomarker Working Group.